Skip to main content

Table 4 Drug-Related Adverse Events in 33 Assessable Patients

From: Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer

Adverse Event

Grade 1

Grade 2

Grade 3

Grade 4

 

No.

%

No.

%

No.

%

No.

%

Skin

        

   Rash

3

9.1

3

9.1

1

3.0

0

0

   Pruritus

2

6.1

2

6.1

0

0

0

0

   Dry skin

1

3.0

0

0

0

0

0

0

   Acne

1

3.0

1

3.0

0

0

0

0

Digestive

        

   Diarrhea

5

15.2

1

3.0

0

0

1

3.0

   Nausea

2

6.1

1

3.0

1

3.0

0

0

   Vomiting

0

0

0

0

1

3.0

0

0

   Anorexia

2

6.1

0

0

0

0

0

0

   Costiveness

1

3.0

0

0

0

0

0

0

Metabolic

        

   Increased ALT

1

3.0

0

0

0

0

0

0

   Increased AST

1

3.0

0

0

0

0

0

0